Loading market dashboard
IXICO plc
PHYOFHealthcareOTCGB
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
Percheron Therapeutics Ltd (ASX:PER, OTC:PERCF) has secured a proposed international nonproprietary name (pINN) from the World Health Organization for its...
Walmart Inc (NYSE:WMT, XETRA:WMT) had its price target lowered by UBS to $141 from $147 following the company’s first-quarter results, while the broker said...
IXICO PLC (LSE:IXI, OTC:PHYOF, FRA:PYPB) CEO, Bram Goorden, talked with Proactive about the company’s interim results, highlighting strong revenue growth,...
IXICO PLC (LSE:IXI, OTC:PHYOF, FRA:PYPB) CEO, Bram Goorden, talked with Proactive about the company's interim results, highlighting strong revenue growth, expanding demand in Alzheimer's disease clinical trials and the company's evolving TechBio strategy. Goorden said IXICO delivered “23% growth of revenues” alongside “38% growth of order book versus the same half last year,” adding that the company now has visibility over “95%” of expected revenues for financial year 2026.
IXICO plc (PHYOF) Q2 2026 Earnings Call Transcript
Zscaler Inc. (NASDAQ:ZS) is expected to deliver a strong fiscal third quarter when it reports results on May 26, with Jefferies analysts saying the...
IXICO PLC (LSE:IXI, OTC:PHYOF, FRA:PYPB), the neuroscience imaging and analytics group, has secured £1.3 million of new contract work that its broker says should take the company's order book close to full coverage of its current-year revenue forecast. The two wins, an Alzheimer's disease biomarker validation contract and an extension to an existing phase II Huntington's disease clinical trial, were announced earlier on Wednesday.
IXICO PLC (LSE:IXI, OTC:PHYOF, FRA:PYPB), the neuroscience imaging and analytics group, has secured a contract win and a contract extension worth a combined £1.3 million over two years. The London-based company will provide amyloid PET imaging analytics to validate a new blood-based biomarker test for Alzheimer's disease on behalf of a global diagnostics and life sciences company, with the work aimed at supporting FDA regulatory clearance.
UK utility shares face a potentially extended period of political and financial pressure after suffering their fourth-largest single-day decline since...
Shares in IXICO PLC (LSE:IXI, OTC:PHYOF, FRA:PYPB), the neuroscience imaging and biomarker analytics specialist, rose as much as 11% after interim results...
Shares in IXICO PLC (LSE:IXI, OTC:PHYOF, FRA:PYPB), the neuroscience imaging and biomarker analytics specialist, rose as much as 11% after interim results showed the company's order book at its highest level since 2021, prompting its house broker to describe full-year estimates as conservative. The company reported revenue up 23% to £3.9 million in the six months to 31 March, with gross margin improving to 53.2% from 49.6% as a higher proportion of analysis-related work, which carries stronger margins, came through the mix.
IXICO PLC (LSE:IXI, OTC:PHYOF, FRA:PYPB), a specialist in neuroscience imaging and biomarker analytics for clinical drug trials, said it expects to deliver at least 15% revenue growth for the full year as it advances plans to open new income streams from its AI-driven platform. Chief executive Bram Goorden said a £10 million capital raise completed in April would allow the company to accelerate a "TechBio" strategy focused on integrating its IXI platform with third-party clinical trial systems and healthcare providers, stressing the funds were not needed to sustain current operations.
Rigetti Computing (NASDAQ:RGTI) reported first quarter results that came in above analyst expectations, as the company continued to scale its...
IXICO PLC (LSE:IXI, OTC:PHYOF, FRA:PYPB), the neuroscience imaging and biomarker analytics company, has released the tenth version of its proprietary IXI...
IXICO PLC (LSE:IXI, OTC:PHYOF, FRA:PYPB), the neuroscience imaging and biomarker analytics company, has released the tenth version of its proprietary IXI platform, bringing improvements to processing speed, data capacity and image analysis precision. The London-based group uses artificial intelligence to help pharmaceutical companies develop drugs for neurological disorders, including Alzheimer's, Parkinson's and Huntington's disease.
After IXICO PLC (LSE:IXI, OTC:PHYOF, FRA:PYPB) reported a strong first half, with revenue growth and a rising order book pointing to increasing momentum in...
After IXICO PLC (LSE:IXI, OTC:PHYOF, FRA:PYPB) reported a strong first half, with revenue growth and a rising order book pointing to increasing momentum in its core clinical trials business, CEO Bram Goorden joined Proactive to discuss the drivers behind the performance. These included contract wins, scaling analytics, and expansion into later-stage studies.
Lindian Resources Ltd (ASX:LIN, OTC:LINIF) has secured an US$11.6 million (~A$16.6 million) equipment finance and working capital facility from Malawi-based...
4:25pm: Peace talks on hold US stocks finished Tuesday’s session lower following reports that peace talks between the US and Iran have been put on hold....
Eli Lilly and Co (NYSE:LLY)’s acquisition of Kelonia Therapeutics is being seen as a positive step for long-term pipeline building, even as the target’s...
Rivian Automotive Inc (NASDAQ:RIVN)’s reported push to offer its electrical architecture and autonomous software to other automakers is unlikely to gain...
Xcel Energy Inc (NASDAQ:XEL) had its price target raised to $91 from $89 by UBS analysts who say the stock continues to offer upside driven by earnings...
Procter & Gamble Co (NYSE:PG, XETRA:PRG) is set to report fiscal third-quarter earnings on April 24, with investors watching for signs that steady category...
McDonald's Corp (NYSE:MCD, XETRA:MDO) is expected to report first-quarter earnings slightly below Wall Street expectations, as analysts at Jefferies trimmed...
Halliburton Company (NYSE:HAL, XETRA:HAL) reported first-quarter profit and revenue above Wall Street expectations on Tuesday, as strength in both North...
Cavendish has retained its buy rating and 26p price target on IXICO PLC (LSE:IXI, OTC:PHYOF, FRA:PYPB) following a first-half trading update that the broker...
Uranium American Resources Inc. (OTC:UARI) said it has completed the acquisition of JAG Minerals Pty Ltd, securing full ownership of its US subsidiary and...
Cavendish has retained its buy rating and 26p price target on IXICO PLC (LSE:IXI, OTC:PHYOF, FRA:PYPB) following a first-half trading update that the broker described as demonstrating strong continued revenue growth, with the neuroscience imaging and analytics company trading in line with full-year expectations. The company reported first-half revenues expected to reach £3.9 million, up 23% year on year, driven by new contract wins, extensions and increased biomarker analysis activity, the measurement of biological indicators used to track neurological disease progression in clinical trials.
IXICO PLC (LSE:IXI, OTC:PHYOF, FRA:PYPB), the neuroscience imaging and data analytics company, has reported strong first-half trading with revenues expected to rise 23% to £3.9 million for the six months ended 31 March. The company said growth was driven by new contract wins, contract extensions and increased volumes of biomarker analysis, the measurement of biological indicators used to track disease progression in clinical trials.
Biogen Inc (NASDAQ:BIIB, XETRA:IDP) will acquire Apellis Pharmaceuticals Inc (NASDAQ:APLS) for $41 per share in cash, in a deal valued at approximately $5.6...
IXICO PLC (LSE:IXI, OTC:PHYOF, FRA:PYPB), the neurology imaging and data analytics specialist, is raising £10 million to fund a strategic push beyond its established contract research business, with Cavendish arguing the move could unlock a market opportunity up to ten times larger than the company currently addresses. The fundraise, structured as a conditional equity placing with a retail offer open to raise up to a further £0.5 million, will bankroll a shift towards what the company calls a "TechBio" model, in which its proprietary AI-driven IXI Platform is licensed or subscribed to by larger companies operating in the broader clinical trial management and clinical decision support markets.
IXICO PLC (LSE:IXI, OTC:PHYOF, FRA:PYPB), the neuroscience imaging and analytics company, is raising up to £10.5 million through a combination of placings, a director subscription and a retail offer, as it seeks to accelerate development of its artificial intelligence-driven IXI platform and pursue US regulatory approval. The investment round comprises an initial placing of £2.8 million and a £0.1 million subscription by certain directors, both priced at 8p per share, representing a 1.6% premium to the closing price of 7.875p on Monday (30 March).
IXICO PLC (LSE:IXI, OTC:PHYOF, FRA:PYPB) CEO Bram Goorden joined Proactive to discuss the company's new strategic collaboration with Medidata and its implications for growth. The partnership brings together IXICO's neuroimaging analytics with Medidata's global clinical trial platform.
IXICO PLC (LSE:IXI, OTC:PHYOF, FRA:PYPB) CEO Bram Goorden joined Proactive to discuss the company’s new strategic collaboration with Medidata and its...
Reddit Inc (NYSE:RDDT) is rolling out new identity verification features aimed at confirming users are human while maintaining user privacy. The changes...
12:10pm: Inflation persists "Despite high oil prices the OECD sees modest growth ahead but raises its inflation forecast, putting pressure on stock...
IXICO PLC (LSE:IXI, OTC:PHYOF, FRA:PYPB), the neuroscience imaging and biomarker analytics company, has announced a technology collaboration with Medidata, a Dassault Systèmes brand and leading provider of clinical trial software to the life sciences industry. The partnership will integrate IXICO's IXI Platform with the Medidata Platform, creating a unified neuroimaging data and analysis system for biopharma companies running clinical trials in neurological disorders.
IXICO PLC (LSE:IXI, OTC:PHYOF, FRA:PYPB), the neuroscience imaging and biomarker analytics company, has announced a technology collaboration with Medidata,...
